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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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ABSTRACT
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired, autoimmune peripheral neuropathy. 
It has an insidious disease progression resulting in a debilitating illness. It is a well known neurological disorder. The 
causative factors are elucidating and it is generally considered idiopathic. However, its’ associations with various 
systemic disorders is well established albeit under recognized, especially with lupus as evident by few of the case 
reports/ series published in the recent past. The aim of this report is to highlight this neglected but important aspect of 
clinical neurology in common practice.
Key words: Chronic inflammatory demyelinating polyneuropathy: lupus; Intravenous immunoglobulin; pulse therapy; 
plasma exchange; steroids; immunosuppressant.
INTRODUCTION
While chronic inflammatory demyelinating polyneuropa-
thy (CIDP) has been exclusively studied, the tempo-
spatial relationship between CIDP and connective 
tissue diseases especially systemic lupus erythematosis 
(SLE) is still an active research subject emphasizing the 
importance of its identification as a possible cause of 
CIDP. SLE is a multisystemic, autoimmune disease that 
can affect the peripheral nervous system(1,2). The term 
“CIDP with lupus” has been used in the category of 
“CIDP with systemic diseases” but only a handful of 
case reports/ series have been published so far (2,3). By 
this report, we aim to share our own experience of a 
patient of CIDP with lupus in order to highlight this 
neglected but important aspect of clinical neurology in 
common practice.
CASE PRESENTATION
A 17 years old girl presented to us with numbness and 
progressive weakness of both the arms and legs for the 
last 6 months in January 2011. She had generalized 
edema for the last 2 months as well. Her motor power 
in upper limbs was 2/5 while that in the lower was 1/5 
with absent reflexes and flexor plantar responses. She 
had microscopic hematuria and proteinuria with low C3 
and C4. In the light of she having urinary findings with 
hypocomplimentemia, her ANA and anti-dsDNA were 
done, both of which turned out to be positive. Rest of 
the autoimmune work-up was negative. (Table 1) Nerve 
conduction studies (NCS) revealed markedly prolonged 
distal latencies with markedly reduced velocities and 
amplitudes of both the median motor nerves. There was 
no response in both peroneal and tibial nerves. Median 
and ulnar nerves did not show any F wave responses. 
The sensory median and ulnar nerves also showed no 
responses. NCS was clearly suggestive of demyelinating 
polyneuropathy and electromyography was therefore 
not conducted. (Table 2)CSF showed albuminocytological 
dissociation. Considering insidious onset and gradual 
progression of symmetrical proximal and distal weak-
ness and sensory dysfunction of all extremities over a 
course of more than 8 weeks; clinically absent tendon 
reflexes in all extremities and NCS showing motor distal 
latency prolongation ≥ 50% above upper limit of 
normal in two nerves plus reduction of motor conduction 
velocity ≥ 30% below lower limit of normal in two 
nerves; with all the exclusion criteria fulfilled; the 
patient was labeled as CIDP. (Table 2) Autoimmune 
workup confirmed SLE with lupus nephritis. (Table 1) 
Table 1: Lab parameters of our patient shown serially 
with time
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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
Acknowledgment: Authors thank the Yazd branch of 
Islamic Azad University for supporting this project.
REFERENCES 
1-   Delbari A, Salman Roghani R,  et al. Stroke epidemiology 
     and one-month fatality among an urban population 
     in Iran. Int J Stroke 2011;6(3):195-200.
2-   Ankolekar S, Geeganage C, Anderton P, Hogg C, 
     Bath PM. Clinical trials for preventing post stroke 
     cognitive impairment. J Neurol Sci. 2010 15;299 
     (1-2):168-74.
3-   Stephens S, Kenny RA, Rowan E, Allan L, Kalaria 
     RN, Bradbury M, Ballard CG. Neuropsychological 
     characteristics of mild vascular cognitive impairment 
     and dementia after stroke. Int J Geriatr Psychiatry. 
     2004 Nov;19(11):1053-7.
4-   Erkinjuntti T. Diagnosis and management of vascular 
     cognitive impairment and dementia. J Neural 
     Transm Suppl. 2002;(63):91-109.
5-   Leys D, Hénon H, Mackowiak-Cordoliani MA, 
     Pasquier F. Poststroke dementia. Lancet Neurol. 
     2005 Nov;4(11):752-9.
6-   Román GC. Facts, myths, and controversies in 
     vascular dementia. J Neurol Sci. 2004 Nov 15; 
     226(1-2):49-52.
7-   Hénon H, Pasquier F, Leys D: Poststroke dementia. 
     Cerebrovasc Di 2006;22:61-70.
8-   Barba R, Martinez-Espinoza S, Rodriguez Garcia E, 
     Pondal M, Vivancos J, Del Ser T: Poststroke 
     dementia: clinical features and risk factors. Stroke 
     2000; 31: 1494–1501.
9-   Peters N, Dichgans M. Vascular dementia. Nervenarzt. 
     2010 Oct;81(10):1245-53; quiz 1254-5.
10- Pendlebury ST, Rothwell PM: Prevalence, 
     incidence, and factors associated with pre-stroke 
     and post-stroke dementia: a systematic review and 
     meta-analysis. Lancet Neuro 2009;8:1006-1018.
11- Klimkowicz-Mrowiec A, Dziedzic T, Słowik A, 
     Szczudlik A. Predictors of poststroke dementia: 
     results of a hospital-based study in poland. 
     Dement Geriatr Cogn Disord. 2006;21(5-6): 
     328-34.
12- Lindén T, Skoog I, Fagerberg B, Steen B, Blomstrand 
     C. Cognitive impairment and dementia 20 months 
     after stroke. Neuroepidemiology. 2004  ;23 
     (1-2):45-52.
13- Desmond DW, Moroney JT, Paik MC, Sano M, Mohr 
     JP, Aboumatar S, Tseng CL, Chan S, Williams JB, 
     Remien RH, Hauser WA, Stern Y. Frequency and 
     clinical determinants of dementia after ischemic 
     stroke. Neurology. 2000;14;54(5):1124-31.
14- Madureira S, Guerreiro M, Ferro JM: Dementia and 
     cognitive impairment three months af ter stroke. 
     Eur J Neurol 2001; 8: 621–627.
15- Lin JH, Lin RT, Tai CT, Hsieh CL, Hsiao SF,Liu CK: 
     Prediction of poststroke dementia. Neurology 
     2003;61: 343–348. 
16- Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, 
     Vataja R, Kaste M: Clinical determinants of 
     poststroke dementia. Stroke 1998;29:75–81. 
17- Snaphaan L, de Leeuw FE. Poststroke memory 
     function in nondemented patients: a systematic 
     review on frequency and neuroimaging correlates. 
     Stroke. 2007  ;38(1):198-203
18- De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi 
     D, Ferrari B, Dalmonte E, Fratiglioni L: The 
     combined effect of age, education, and stroke on 
     dementia and cognitive impairment no dementia 
     in the elderly. Dement Geriatr Cogn Disor 2007; 
     24:266-273 
19- Pasi M, Poggesi A, Salvadori E, Pantoni L. Post 
     stroke dementia and cognitive impairment. Front 
     Neurol Neurosci. 2012;30:65-9.
20- Desmond DW, Bagiella E, Moroney JT, Stern Y: The 
     effect of patient attrition on estimates of the 
     frequency of dementia following stroke. Arch 
     Neuro 1998;55:390-394
21- Pendlebury ST. Stroke-related dementia: Rates, 
     risk factors and implications for future research. 
     Maturitas. 2009 ;20;64(3):165-71
22- Igoumenou A, Ebmeier KP. Diagnosing and managing 
     vascular dementia. Practitioner. 2012 ;256 
     (1747):13-6, 2.
23- Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, 
     Eiklid KL, Fure B, Stensrød B, Engedal K. Association 
     between ApoE epsilon4 and cognitive impairment 
     after stroke. Dement Geriatr Cogn Disord. 
     2009;27(6):525-33.
24- Makin SD, Turpin S, Dennis MS, Wardlaw JM. 
     Cognitive impairment after lacunar stroke: systematic 
     review and meta-analysis of incidence, prevalence 
     and comparison with other stroke subtypes. J 
     Neurol Neurosurg Psychiatry. 2013 ;84 (8):893-900
25- Cumming TB, Brodtmann A. Can stroke cause 
     neurodegenerative dementia? Int J Stroke. 2011 
     ;6 (5):416-24.
26- Desmond DW, Moroney JT, Paik MC, Sano M, Mohr 
     JP, Aboumatar S, Tseng CL, Chan S, Williams JB, 
     Remien RH, Hauser WA, Stern Y: Frequency and 
     clinical determinants of dementia after ischemic 
     stroke. Neurolog 2000;54:1124-1131
Year Lab parameters Value Inference 
Jan. 2011 
ANA 13.31 IU/l (normal < 1.5 IU/l) +ve 
ESR 56 mm/ 1
sthr (normal < 20 
mm) High 
Anti ds DNA 72 IU/l (normal < 20 IU/ml) +ve 
C3 level 0.69 g/l (normal 0.83-1.93- g/l) Low 
C4 level 0.07 g/l (normal 0.15-0.57 g/l) Low 
Anti Sm 0.0 g/l -ve 
Anti-RNP 0.0 g/l -ve 
Anti SSA 0.0 g/l -ve 
Anti SSB 0.0 g/l -ve 
Anti Jo 1 0.0 g/l -ve 
Anti Sc 70 0.0 g/l -ve 
c-ANCA 0.0 g/l -ve 
p-ANCA 0.0 g/l -ve 
Anti GBM 0.0 g/l -ve 
AMA 0.0 g/l -ve 
ASMA 0.0 g/l -ve 
Proteinuria 3.12 g/l (normal < 0.3 g/l) Nephrotic range 
WBC 7900/ ul Normal 
Hb 12.2g/dl Normal 
Platelets 214000/ul Normal 
Bilirubin 0.30 mg/dl Normal 
ALT 17 U/l Normal 
Alkaline phosphatase 39 U/l Normal 
Urea 20 mg/dl Normal 
Creatinine 0.30 mg/dl Normal 
U/S abdomen - Ascitis + pleural effusion 
Jun. 2011 
ANA 9.12 IU/l +ve 
Anti ds DNA 61.6 IU/l +ve 
ESR 36 mm/ 1sthr High 
C3 level 0.29 g/l Low 
C4 level 0.13 g/l Low 
Proteinuria 1.56 g/l Subnephrotic range 
Urea 20 mg/dl Normal 
Creatinine 0.30 mg/dl Normal 
U/S abdomen - Unremarkable study 
Jun. 2014 
ANA 10.30 IU/l +ve 
Anti ds DNA 54.8 IU/l +ve 
Proteinuria Nil -ve 
NCS of June 2011 
Motor Nerves 
Site NR 
Onse
t 
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N. 
onse
t 
(ms) 
O-P 
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mp 
(mV) 
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Dur 
(ms) 
Segment 
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a-O 
(ms) 
Dist 
(cm) 
Vel 
(m/s
2) 
N. 
Vel 
(m/s
2) 
Right Median (APB) 
Wrist - 8.98 
< 4.2 
0.88 
> 5.0 
6.72 Elbow-
Wrist 
11.1
7 25 
22.3
8 
> 
50.0 Elbow - 20.16 0.22 8.20 
Right Ulnar (ADM) 
Wrist - 5.55 
< 4.2 
1.80 
> 3.0 
7.66 B Elbow-
Wrist 6.02 24 
39.8
7 
> 
53.0 B Elbow - 11.56 1.47 9.45 
Right Peroneal (EDB) 
Ankle NR - 
< 5.5 
- 
> 2.5 
- 
- - - - > 40 B Fib NR - - - 
P-TA NR - - - 
Right Tibial (AHB) 
Ankle NR - < 6.0 - > 3.0 - - - - - > 41 Knee NR - - - 
Left Tibial (AHB) 
Ankle NR - < 6.0 - > 3.0 - - - - - > 41 Knee NR - - - 
Left Median (APB) 
Wrist - 10.55 < 4.2 
0.31 
> 5.0 
6.41 Elbow-
Wrist 
12.0
3 24 
19.9
5 
> 
50.0 Elbow - 22.58 0.18 7.27 
Sensory Nerves 
Site NR Peak (ms) 
N. 
Peak 
(ms) 
PT-
Amp 
(µV) 
N. 
Amp 
(µV) 
- Segment Name 
Delt
a-P 
(ms) 
Dist 
(cm) 
Vel 
(m/s
2) 
N. 
Vel 
(m/s
2) 
Right Median Anti (2nd digit) 
Wrist NR - < 3.7 - >15.0 - - - - - > 39 
Right Ulnar Anti 
(5th digit) NR - < 3.7 - 
>  
15.0 - - - - - > 50 
Left Median Anti (2nd digit) 
Wrist NR - < 3.7 - >  15.0 - - - - - > 39 
Left Ulnar Anti (5th digit) 
Wrist NR - < 3.7 - >  15.0 - - - - - > 50 
Table 1: Lab parameters of our patient shown serially 
with time: starting from January 2011 to June 2014. 
Table 2: Nerve conduction studies of our patient revealing 
features of CIDP in 2011
Table 2: Nerve conduction studies in 2011: NR = No 
response; N.= Normal; Amp = Amplitude; Neg. = 
Negative; Dur. = Duration; O = Onset; P = Peak; Dist 
= distance; Vel = Velocity; APB = Abductor PolicisBre-
vis; ADM = Abductor DigitiMinimi; EDB = Extensor 
DigitorumBrevis; AHB = Abductor HallucisBrevis.
Thus, consolidated diagnosis was that of CIDP with 
lupus. She was given 1g methylprednisolone for 3 days. 
Her limb power gradually improved and proteinuria 
markedly decreased until she was able to walk without 
any functional disability as estimated using modified 
Rankin Scale (mRS) over a period of 4 weeks. She was 
discharged on maintenance dose of oral prednisone 
(1mg/kg/day) and 500 mg of cyclosporine three times 
daily. On follow-up visits after 3 months, the patient 
showed well controlled lupus with no renal or neurological 
impairment. Dose of prednisone was tapered down to 
10 mg per day and cyclosporin continued with well 
controlled symptoms for both CIDP and SLE on 3 
monthly follow-ups. After 30 months from initial diagnosis, 
the patient again presented with progressive weakness 
and numbness of all four limbs for the last 45 days, 
following a lower respiratory type infection. Her motor 
power in upper limbs was 4/5 while that in the lower 
was 2/5 with absent reflexes and flexor plantar 
responses. She, however, did not show any symptoms, 
signs or lab abnormalities suggesting renal compromise 
this time. (Table 1) Repeat NCS showed markedly 
prolonged distal latencies with reduced voltage and 
markedly reduced velocities in both median nerves and 
ulnar nerves. Peroneal and tibial nerves showed no 
response and median and ulnar nerves did not show 
any F wave responses. There was a conduction block 
from right median motor nerve; an electrophysiological 
hallmark of acquired demyelination. The sensory 
median and ulnar nerves also showed no responses. 
(Table 3) CSF showed albuminocytological dissociation. 
Her plasma exchange was done (200-250 ml/kg) with 
gradual improvement of symptoms until she was able to 
walk without support. She was discharged and put on 
maintenance dose of prednisone 1mg/kg/day plus 1g 
methyprednisolone once monthly. On routine follow-
ups, patient showed marked recovery with resolution of 
neurological symptoms and regain of full functional 
status over the next 6 months.
Table 3: Nerve conduction studies of our patient reveal-
ing features of CIDP in 2014
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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
Acknowledgment: Authors thank the Yazd branch of 
Islamic Azad University for supporting this project.
REFERENCES 
1-   Delbari A, Salman Roghani R,  et al. Stroke epidemiology 
     and one-month fatality among an urban population 
     in Iran. Int J Stroke 2011;6(3):195-200.
2-   Ankolekar S, Geeganage C, Anderton P, Hogg C, 
     Bath PM. Clinical trials for preventing post stroke 
     cognitive impairment. J Neurol Sci. 2010 15;299 
     (1-2):168-74.
3-   Stephens S, Kenny RA, Rowan E, Allan L, Kalaria 
     RN, Bradbury M, Ballard CG. Neuropsychological 
     characteristics of mild vascular cognitive impairment 
     and dementia after stroke. Int J Geriatr Psychiatry. 
     2004 Nov;19(11):1053-7.
4-   Erkinjuntti T. Diagnosis and management of vascular 
     cognitive impairment and dementia. J Neural 
     Transm Suppl. 2002;(63):91-109.
5-   Leys D, Hénon H, Mackowiak-Cordoliani MA, 
     Pasquier F. Poststroke dementia. Lancet Neurol. 
     2005 Nov;4(11):752-9.
6-   Román GC. Facts, myths, and controversies in 
     vascular dementia. J Neurol Sci. 2004 Nov 15; 
     226(1-2):49-52.
7-   Hénon H, Pasquier F, Leys D: Poststroke dementia. 
     Cerebrovasc Di 2006;22:61-70.
8-   Barba R, Martinez-Espinoza S, Rodriguez Garcia E, 
     Pondal M, Vivancos J, Del Ser T: Poststroke 
     dementia: clinical features and risk factors. Stroke 
     2000; 31: 1494–1501.
9-   Peters N, Dichgans M. Vascular dementia. Nervenarzt. 
     2010 Oct;81(10):1245-53; quiz 1254-5.
10- Pendlebury ST, Rothwell PM: Prevalence, 
     incidence, and factors associated with pre-stroke 
     and post-stroke dementia: a systematic review and 
     meta-analysis. Lancet Neuro 2009;8:1006-1018.
11- Klimkowicz-Mrowiec A, Dziedzic T, Słowik A, 
     Szczudlik A. Predictors of poststroke dementia: 
     results of a hospital-based study in poland. 
     Dement Geriatr Cogn Disord. 2006;21(5-6): 
     328-34.
12- Lindén T, Skoog I, Fagerberg B, Steen B, Blomstrand 
     C. Cognitive impairment and dementia 20 months 
     after stroke. Neuroepidemiology. 2004  ;23 
     (1-2):45-52.
13- Desmond DW, Moroney JT, Paik MC, Sano M, Mohr 
     JP, Aboumatar S, Tseng CL, Chan S, Williams JB, 
     Remien RH, Hauser WA, Stern Y. Frequency and 
     clinical determinants of dementia after ischemic 
     stroke. Neurology. 2000;14;54(5):1124-31.
14- Madureira S, Guerreiro M, Ferro JM: Dementia and 
     cognitive impairment three months af ter stroke. 
     Eur J Neurol 2001; 8: 621–627.
15- Lin JH, Lin RT, Tai CT, Hsieh CL, Hsiao SF,Liu CK: 
     Prediction of poststroke dementia. Neurology 
     2003;61: 343–348. 
16- Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, 
     Vataja R, Kaste M: Clinical determinants of 
     poststroke dementia. Stroke 1998;29:75–81. 
17- Snaphaan L, de Leeuw FE. Poststroke memory 
     function in nondemented patients: a systematic 
     review on frequency and neuroimaging correlates. 
     Stroke. 2007  ;38(1):198-203
18- De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi 
     D, Ferrari B, Dalmonte E, Fratiglioni L: The 
     combined effect of age, education, and stroke on 
     dementia and cognitive impairment no dementia 
     in the elderly. Dement Geriatr Cogn Disor 2007; 
     24:266-273 
19- Pasi M, Poggesi A, Salvadori E, Pantoni L. Post 
     stroke dementia and cognitive impairment. Front 
     Neurol Neurosci. 2012;30:65-9.
20- Desmond DW, Bagiella E, Moroney JT, Stern Y: The 
     effect of patient attrition on estimates of the 
     frequency of dementia following stroke. Arch 
     Neuro 1998;55:390-394
21- Pendlebury ST. Stroke-related dementia: Rates, 
     risk factors and implications for future research. 
     Maturitas. 2009 ;20;64(3):165-71
22- Igoumenou A, Ebmeier KP. Diagnosing and managing 
     vascular dementia. Practitioner. 2012 ;256 
     (1747):13-6, 2.
23- Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, 
     Eiklid KL, Fure B, Stensrød B, Engedal K. Association 
     between ApoE epsilon4 and cognitive impairment 
     after stroke. Dement Geriatr Cogn Disord. 
     2009;27(6):525-33.
24- Makin SD, Turpin S, Dennis MS, Wardlaw JM. 
     Cognitive impairment after lacunar stroke: systematic 
     review and meta-analysis of incidence, prevalence 
     and comparison with other stroke subtypes. J 
     Neurol Neurosurg Psychiatry. 2013 ;84 (8):893-900
25- Cumming TB, Brodtmann A. Can stroke cause 
     neurodegenerative dementia? Int J Stroke. 2011 
     ;6 (5):416-24.
26- Desmond DW, Moroney JT, Paik MC, Sano M, Mohr 
     JP, Aboumatar S, Tseng CL, Chan S, Williams JB, 
     Remien RH, Hauser WA, Stern Y: Frequency and 
     clinical determinants of dementia after ischemic 
     stroke. Neurolog 2000;54:1124-1131
Table 3: Nerve conduction studies in 2014: NR = No 
response; N.= Normal; Amp = Amplitude; Neg. = 
Negative; Dur. = Duration; O = Onset; P = Peak; Dist 
= distance; Vel= Velocity; APB = Abductor PolicisBre-
vis; ADM = Abductor DigitiMinimi; EDB = Extensor 
DigitorumBrevis; AHB = Abductor HallucisBrevis.
DISCUSSION
Chronic inflammatory demyelinating polyneuropathy is 
an acquired immune-mediated inflammatory disorder 
of the peripheral nervous system. CIDP is at times 
considered the chronic subset of acute inflammatory 
demyelinating polyneuropathy (AIDP), most common 
form of which is GuillainBarré syndrome (GBS). (4, 5, 6) 
CIDP is under-recognized and under-treated due to its 
heterogeneous presentation (both clinical and electro-
physiological) and the limitations of clinical, serologic, 
and electrophysiologic diagnostic criteria. (15) While 
difficult to diagnose earlier in its course, timely treat-
ment is important in preventing irreversible axonal loss 
and improving functional recovery. (7, 8, 9) The pathologic 
hallmark of the disease is loss of the myelin sheath of 
peripheral nerves. (3,6) As a result of immune action, 
affected nerves demyelinate and fail to respond or 
respond only weakly to stimuli causing numbness, 
tingling, pain, progressive muscle weakness and loss of 
deep tendon reflexes. Weakness in CIDP is both proxi-
mal and distal; a hallmark of acquired demyelinating 
polyneuropathy. Cranial nerve and bulbar involvement 
occurs in 10-20% of patients only. Sometimes, CIDP 
presents with back pain and rarely with symptoms of 
lumbar canal stenosis and caudaequina syndrome 
suggestive of nerve root hypertrophy and requires 
neurosurgical intervention. Autonomic involvement in 
CIDP is generally mild and limited. Impaired bowel and 
bladder control usually are not the presenting symptoms 
and rather appear late in severe cases. (4, 8, 9, 10) Most 
patients with CIDP exhibit a slowly progressive course, 
but a relapsing-remitting course, relapsing/ recurrent 
AIDP like episodes exist in at least one-third of patients. 
Such an observation is more common in younger 
patients. The accession of early treatment for CIDP has 
made the temporal progression of the disease more 
difficult to characterize and categorize, since remissions 
may be related to therapy rather than to the natural 
course of the disease. This is why it’s almost always 
impossible for neurophysicians to differentiate between 
the two on first visit. (7, 8) The treatment of CIDP requires 
a systemic approach including the prevention of further 
demyelination and recovery of functional disability using 
exercise, occupational and physical therapy. In general, 
it includes an induction phase, long term management 
plan and supportive care. (9, 10) It is only in recent past 
that physicians have been able to appreciate association 
of the disease with lupus.The combination can present 
either way; diagnosed SLE followed or complicated by 
CIDP or vice versa. That is why it is extremely important 
for physicians to be aware of this association as general 
weakness due to multisystem involvement in SLE as a 
part of chronic ailment is often blamed to be the cause 
behind motor weakness whereas the real problem lies 
undiagnosed. This is said so because it is a potentially 
treatable disease that can greatly improve the quality of 
life for such patients and reduce morbidity associated 
with functional disability. (9, 10) As such cases can pose 
difficulty in diagnosis at times, whenever in doubt, 
physicians should have a low threshold of suspicion and 
timely refer such cases for specialist care.
CONCLUSIONS
Successful management of CIDP with lupus requires 
high degree of suspicion to correctly diagnose and 
thereafter manage such cases. This may at times 
require the expertise of a trained neurologist and therefore 
physicians should not hesitate to timely refer such 
cases for specialist care.
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) 
Right Median (APB) 
Wrist - 9.38 
< 4.2 
1.90 
> 5.0 
7.73 Elbow-
Wrist 8.28 20.5 
24.7
6 
> 
50.0 Elbow - 17.66 0.85 7.73 
Right Ulnar (ADM) 
Wrist - 3.67 
< 4.2 
4.04 
> 3.0 
7.89 B Elbow-
Wrist 7.27 22 
30.2
6 
> 
53.0 B Elbow - 10.94 3.27 9.38 
Right Peroneal (EDB) 
Ankle NR - 
< 5.5 
- 
> 2.5 
- 
- - - - > 40 B Fib NR - - - 
P-TA NR - - - 
Right Tibial (AHB) 
Ankle NR - < 6.0 - > 3.0 - - - - - > 41 Knee NR - - - 
Left Median (APB) 
Wrist - 8.52 
< 4.2 
1.82 
> 5.0 
4.53 Elbow-
Wrist 7.89 20.5 
25.9
8 
> 
50.0 Elbow - 16.41 1.69 5.47 
Left Ulnar (ADM) 
Wrist - 5.23 
< 4.2 
4.42 
> 3.0 
6.56 B Elbow-
Wrist 7.89 22.5 
28.5
2 
> 
53.0 B Elbow - 13.13 4.16 7.19 
Sensory Nerves 
 NR Peak (ms) 
N. 
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(ms) 
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(µV) 
N. 
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(µV) 
- Segment Name 
Delt
a-P 
(ms) 
Dist 
(cm) 
Vel 
(m/s
2) 
N. 
Vel 
(m/s
2) 
Right Median Anti (2nd digit) 
Wrist NR - < 3.7 - >  15.0 - - - - - > 39 
Right Ulnar Anti 
(5th digit) NR - < 3.7 - 
> 
15.0 - - - - - > 50 
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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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Table 3: Nerve conduction studies in 2014: NR = No 
response; N.= Normal; Amp = Amplitude; Neg. = 
Negative; Dur. = Duration; O = Onset; P = Peak; Dist 
= distance; Vel= Velocity; APB = Abductor PolicisBre-
vis; ADM = Abductor DigitiMinimi; EDB = Extensor 
DigitorumBrevis; AHB = Abductor HallucisBrevis.
DISCUSSION
Chronic inflammatory demyelinating polyneuropathy is 
an acquired immune-mediated inflammatory disorder 
of the peripheral nervous system. CIDP is at times 
considered the chronic subset of acute inflammatory 
demyelinating polyneuropathy (AIDP), most common 
form of which is GuillainBarré syndrome (GBS). (4, 5, 6) 
CIDP is under-recognized and under-treated due to its 
heterogeneous presentation (both clinical and electro-
physiological) and the limitations of clinical, serologic, 
and electrophysiologic diagnostic criteria. (15) While 
difficult to diagnose earlier in its course, timely treat-
ment is important in preventing irreversible axonal loss 
and improving functional recovery. (7, 8, 9) The pathologic 
hallmark of the disease is loss of the myelin sheath of 
peripheral nerves. (3,6) As a result of immune action, 
affected nerves demyelinate and fail to respond or 
respond only weakly to stimuli causing numbness, 
tingling, pain, progressive muscle weakness and loss of 
deep tendon reflexes. Weakness in CIDP is both proxi-
mal and distal; a hallmark of acquired demyelinating 
polyneuropathy. Cranial nerve and bulbar involvement 
occurs in 10-20% of patients only. Sometimes, CIDP 
presents with back pain and rarely with symptoms of 
lumbar canal stenosis and caudaequina syndrome 
suggestive of nerve root hypertrophy and requires 
neurosurgical intervention. Autonomic involvement in 
CIDP is generally mild and limited. Impaired bowel and 
bladder control usually are not the presenting symptoms 
and rather appear late in severe cases. (4, 8, 9, 10) Most 
patients with CIDP exhibit a slowly progressive course, 
but a relapsing-remitting course, relapsing/ recurrent 
AIDP like episodes exist in at least one-third of patients. 
Such an observation is more common in younger 
patients. The accession of early treatment for CIDP has 
made the temporal progression of the disease more 
difficult to characterize and categorize, since remissions 
may be related to therapy rather than to the natural 
course of the disease. This is why it’s almost always 
impossible for neurophysicians to differentiate between 
the two on first visit. (7, 8) The treatment of CIDP requires 
a systemic approach including the prevention of further 
demyelination and recovery of functional disability using 
exercise, occupational and physical therapy. In general, 
it includes an induction phase, long term management 
plan and supportive care. (9, 10) It is only in recent past 
that physicians have been able to appreciate association 
of the disease with lupus.The combination can present 
either way; diagnosed SLE followed or complicated by 
CIDP or vice versa. That is why it is extremely important 
for physicians to be aware of this association as general 
weakness due to multisystem involvement in SLE as a 
part of chronic ailment is often blamed to be the cause 
behind motor weakness whereas the real problem lies 
undiagnosed. This is said so because it is a potentially 
treatable disease that can greatly improve the quality of 
life for such patients and reduce morbidity associated 
with functional disability. (9, 10) As such cases can pose 
difficulty in diagnosis at times, whenever in doubt, 
physicians should have a low threshold of suspicion and 
timely refer such cases for specialist care.
CONCLUSIONS
Successful management of CIDP with lupus requires 
high degree of suspicion to correctly diagnose and 
thereafter manage such cases. This may at times 
require the expertise of a trained neurologist and therefore 
physicians should not hesitate to timely refer such 
cases for specialist care.
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